Skye Bioscience, Inc.
SKYE
$2.23
$0.3518.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 38.80% | -12.66% | -48.18% | -227.19% | -123.02% |
| Total Depreciation and Amortization | -15.77% | -2.54% | 2.68% | 171.06% | 527.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 153.78% | -31.67% | -36.56% | 169.43% | -6.79% |
| Change in Net Operating Assets | -130.02% | 592.85% | 451.61% | -341.07% | 405.12% |
| Cash from Operations | 33.73% | 6.83% | -19.50% | -153.95% | -51.49% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | 99.33% | -- | 28.21% | 25.55% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 158.30% | 185.10% | -- | -- | -- |
| Cash from Investing | 160.24% | 185.07% | -3,201.22% | 651.17% | -36,376.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -65.38% | -- | 100.18% | -- | -- |
| Cash from Financing | -654.95% | -- | 103.57% | -- | 100.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 99.64% | 110.30% | -55.48% | 19.54% | -144.88% |